316 Phase I study of lurbinectedin (PM01183) in combination with cisplatin (C) with or without aprepitant (Ap) in patients (pts) with advanced solid tumors. (September 2015) - Forster, M.; Sessa, C.; Von Moos, R.; Brown, N.; Metaxas, Y.; Griguolo, G.; Lardelli, P.; Coronado, C.; Juan, L.; Fernandez-Teruel, C.; Soto-Matos, A.; Stathis, A.